Composition for use in treating and preventing inflammation related disorder

A method for treating a mammal or human suffering from mucosal inflammation related disorder, comprising administering to said mammal or human a drug suitable for the treatment of mucosal inflammation and a therapeutically effective dose of a hyaluronic acid (HA) mixture which comprises at least two hyaluronic acids including a low average molecular weight HA (LMWHA) and a high average molecular weight HA (HMWHA), wherein said drug is mesalamine, and a dose of said drug is from 250 mg to 1 g per day, wherein the mucosa of the mucosal inflammation is the mucosa of a gastrointestinal tract;

• wherein the HA mixture is of an average molecular weight (MW) between 50 kilo Dalton and 5 million Dalton;
• wherein the mixing ratio of the HA mixture and mesalamine is 0.625:5 by weight;
• wherein the average MW of the LMWHA is between 50 kilo Da and 1.5 million Da, and the average MW of the HMWHA is between 1.5 million Da and 5 million Da, wherein the LMWHA and the HMWHA are apart from each other by at least 0.5 million Da, and wherein the mixing ratio of the LMWHA and the HMWHA is 20:80 by weight.